Aurinia Pharmaceuticals (AUPH) Financials

$12.08 -0.03 (-0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$11.99 -0.09 (-0.74%)

As of 07:44 PM Eastern

Annual Income Statements for Aurinia Pharmaceuticals

This table shows Aurinia Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-23	-71	-54	-88	-103	-181	-108	-78	5.75
Consolidated Net Income / (Loss)	-23	-71	-53	-88	-103	-181	-108	-78	5.75
Net Income / (Loss) Continuing Operations	-23	-71	-54	-88	-103	-181	-108	-78	5.75
Total Pre-Tax Income	-23	-71	-53	-88	-103	-180	-106	-77	7.45
Total Operating Income	-25	-47	-55	-91	-104	-181	-111	-92	-4.69
Total Gross Profit	0.00	0.42	0.46	0.32	50	45	128	161	207
Total Revenue	0.17	0.42	0.46	0.32	50	46	134	176	235
Operating Revenue	0.01	-	0.46	0.32	50	46	134	176	235
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	1.09	5.66	14	28
Operating Cost of Revenue	0.00	-	-	0.00	0.00	1.09	5.66	14	28
Total Operating Expenses	25	47	57	91	154	225	240	253	212
Selling, General & Admin Expense	6.97	12	14	22	97	174	196	195	172
Research & Development Expense	15	34	41	53	50	51	45	50	21
Other Operating Expenses / (Income)	2.21	-0.20	-0.67	15	6.81	0.57	-1.52	8.38	-4.35
Restructuring Charge	-	-	-	-	-	-	0.00	0.00	23
Total Other Income / (Expense), net	1.73	-24	2.23	2.70	1.52	0.53	5.12	14	12
Interest Expense	-	-	-	-	-	0.00	0.00	2.78	4.84
Interest & Investment Income	-	-	2.23	2.70	1.52	0.53	5.12	17	17
Income Tax Expense	-	-	0.07	0.14	-0.09	0.76	1.83	0.55	1.70
Basic Earnings per Share	($0.66)	($0.92)	($0.63)	($0.95)	($0.87)	($1.40)	($0.76)	($0.54)	$0.04
Weighted Average Basic Shares Outstanding	-	84.05M	84.78M	93.02M	118.47M	129.37M	141.92M	143.24M	143.06M
Diluted Earnings per Share	($0.66)	($0.92)	($0.63)	($0.95)	($0.87)	($1.40)	($0.76)	($0.54)	$0.04
Weighted Average Diluted Shares Outstanding	-	84.05M	84.78M	93.02M	118.47M	129.37M	141.92M	143.24M	146.19M
Weighted Average Basic & Diluted Shares Outstanding	-	84.05M	84.78M	93.02M	118.47M	129.37M	142.58M	144.62M	137.34M

This table shows Aurinia Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	-26	-26	-12	-13	-27	-11	0.72	15	0.96	23	22
Consolidated Net Income / (Loss)	-26	-26	-11	-13	-27	-11	0.72	14	1.43	23	22
Net Income / (Loss) Continuing Operations	-26	-26	-11	-13	-27	-11	0.72	14	1.43	23	22
Total Pre-Tax Income	-25	-26	-12	-13	-26	-10	1.48	15	1.17	24	22
Total Operating Income	-28	-30	-16	-16	-30	-13	-1.51	12	-1.67	22	20
Total Gross Profit	27	34	40	48	40	43	48	62	54	54	63
Total Revenue	28	34	41	55	45	50	57	68	60	62	70
Operating Revenue	28	34	41	55	45	50	57	68	60	62	70
Total Cost of Revenue	1.36	0.42	1.56	6.77	5.40	7.75	8.91	6.04	5.55	8.57	7.12
Operating Cost of Revenue	1.36	0.42	1.56	6.77	5.40	7.75	8.91	6.04	5.55	8.57	7.12
Total Operating Expenses	55	64	56	64	69	56	50	50	56	32	43
Selling, General & Admin Expense	47	50	47	48	50	48	45	42	37	20	26
Research & Development Expense	9.87	13	13	14	10	5.55	4.08	3.05	8.11	5.74	7.43
Other Operating Expenses / (Income)	-2.17	0.29	-3.63	2.65	9.07	-4.13	-0.29	4.57	-4.51	4.43	9.25
Restructuring Charge	-	0.00	0.00	0.00	-	6.68	1.07	0.00	15	1.53	0.11
Total Other Income / (Expense), net	2.91	3.81	4.04	3.11	3.26	3.24	2.99	3.06	2.84	2.50	2.07
Interest Expense	-	0.00	0.07	1.40	1.31	1.28	1.20	1.21	1.15	1.07	1.12
Interest & Investment Income	2.91	3.81	4.10	4.51	4.57	4.53	4.19	4.27	3.99	3.57	3.19
Income Tax Expense	0.86	0.44	-0.64	0.30	0.46	0.74	0.76	0.46	-0.26	1.01	0.64
Basic Earnings per Share	($0.18)	($0.18)	($0.08)	($0.09)	($0.19)	($0.07)	$0.01	$0.10	-	$0.17	$0.16
Weighted Average Basic Shares Outstanding	141.92M	142.64M	142.78M	142.85M	143.24M	144.01M	143.33M	143.05M	143.06M	138.92M	134.87M
Diluted Earnings per Share	($0.18)	($0.18)	($0.08)	($0.09)	($0.19)	($0.07)	$0.01	$0.10	-	$0.16	$0.16
Weighted Average Diluted Shares Outstanding	141.92M	142.64M	142.78M	142.85M	143.24M	144.01M	144.11M	145.65M	146.19M	143.20M	137.53M
Weighted Average Basic & Diluted Shares Outstanding	142.58M	143.03M	143.42M	143.61M	144.62M	143.02M	142.99M	143.18M	137.34M	135.10M	131.63M

This table details how cash moves in and out of Aurinia Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	44	126	-48	188	-34	-40	-138	-45	35
Net Cash From Operating Activities	-21	-41	-52	-64	-70	-158	-80	-33	44
Net Cash From Continuing Operating Activities	-21	-41	-52	-64	-70	-158	-80	-33	44
Net Income / (Loss) Continuing Operations	-23	-71	-53	-88	-103	-181	-108	-78	5.75
Consolidated Net Income / (Loss)	-23	-71	-53	-88	-103	-181	-108	-78	5.75
Depreciation Expense	-	0.02	0.02	0.03	1.37	2.76	2.71	12	19
Amortization Expense	1.29	-0.12	1.29	1.14	-	0.66	-1.57	-12	-13
Non-Cash Adjustments To Reconcile Net Income	1.25	30	6.15	22	21	42	34	51	26
Changes in Operating Assets and Liabilities, net	-	-	-6.00	2.03	10	-22	-6.82	-5.61	5.45
Net Cash From Investing Activities	31	-8.00	-0.07	7.78	-158	-104	-61	-6.71	39
Net Cash From Continuing Investing Activities	31	-8.00	-0.07	7.78	-158	-104	-61	-6.71	39
Purchase of Property, Plant & Equipment	-	-0.03	-0.07	-0.09	-7.34	-1.50	-0.29	-0.72	-0.28
Purchase of Investments	-	-98	-36	0.00	-203	-445	-524	-524	-546
Sale and/or Maturity of Investments	31	90	36	7.88	52	354	464	529	585
Other Investing Activities, net	-	-	-	0.00	0.00	-12	-0.66	-12	-0.04
Net Cash From Financing Activities	34	175	4.01	244	194	221	2.43	-5.13	-49
Net Cash From Continuing Financing Activities	34	166	4.01	244	194	221	2.43	-5.13	-49
Repurchase of Common Equity	-	-	-	-	-	-	0.00	0.00	-40
Issuance of Common Equity	7.82	162	0.00	223	188	197	1.91	1.85	1.08
Other Financing Activities, net	-	4.14	4.01	21	6.64	24	0.52	-6.98	-9.94
Cash Income Taxes Paid	-	-	0.00	0.06	0.26	0.26	1.98	0.50	2.18

This table details how cash moves in and out of Aurinia Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Change in Cash & Equivalents	8.12	-5.17	-7.29	-35	2.48	16	-31	3.74	46	-17	-13
Net Cash From Operating Activities	10	-32	-2.83	-13	14	-19	16	17	30	1.30	44
Net Cash From Continuing Operating Activities	10	-32	-2.83	-13	14	-19	16	17	30	1.30	44
Net Income / (Loss) Continuing Operations	-26	-26	-11	-13	-27	-11	0.72	14	1.43	23	22
Consolidated Net Income / (Loss)	-26	-26	-11	-13	-27	-11	0.72	14	1.43	23	22
Depreciation Expense	0.22	0.72	0.72	5.26	4.95	4.85	4.84	4.89	4.86	4.86	4.86
Amortization Expense	-1.56	-2.61	-2.99	-3.24	-3.31	-3.21	-3.13	-3.42	-2.98	-2.66	-2.56
Non-Cash Adjustments To Reconcile Net Income	5.87	9.68	8.82	12	20	1.27	7.62	13	4.32	0.73	15
Changes in Operating Assets and Liabilities, net	32	-13	2.12	-14	19	-11	5.78	-12	22	-25	5.73
Net Cash From Investing Activities	-3.02	25	-5.61	-20	-6.26	49	-39	-11	39	31	-13
Net Cash From Continuing Investing Activities	-3.02	25	-5.61	-20	-6.26	49	-39	-11	39	31	-13
Purchase of Property, Plant & Equipment	-0.13	-0.35	-0.18	0.11	-0.30	-0.01	-	-	-0.28	-0.02	-0.10
Purchase of Investments	-121	-142	-114	-123	-144	-121	-197	-143	-85	-92	-145
Sale and/or Maturity of Investments	118	168	121	103	138	171	158	133	124	123	132
Net Cash From Financing Activities	0.69	1.64	1.14	-2.33	-5.58	-15	-8.27	-2.72	-23	-49	-44
Net Cash From Continuing Financing Activities	0.69	1.64	1.14	-2.33	-5.58	-15	-8.27	-2.72	-23	-49	-44
Repurchase of Common Equity	-	0.00	-	-	-	-12	-6.13	-	-22	-47	-43
Other Financing Activities, net	-1.22	1.64	1.14	-2.33	-7.43	-2.75	-2.14	-2.72	-2.33	-2.42	-2.23
Cash Income Taxes Paid	1.20	0.00	0.28	0.06	0.16	0.00	1.46	-	0.73	0.25	0.82

This table presents Aurinia Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	57	190	146	324	464	543	471	548	551
Total Current Assets	40	175	133	315	419	513	443	425	447
Cash & Equivalents	40	166	118	306	272	232	94	49	83
Short-Term Investments	0.00	7.83	7.89	0.00	126	234	295	302	275
Accounts Receivable	0.09	0.11	0.22	0.37	0.00	15	13	24	37
Inventories, net	-	-	-	0.00	14	19	25	40	39
Prepaid Expenses	-	1.68	6.78	8.75	7.17	12	14	9.49	11
Other Current Assets	-	-	-	-	-	0.80	1.33	1.03	1.13
Plant, Property, & Equipment, net	0.00	0.03	0.04	0.09	4.79	4.42	3.65	3.35	2.73
Total Noncurrent Assets	17	15	13	9.07	39	26	25	120	101
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	0.00	109	92
Intangible Assets	16	14	13	8.86	9.33	8.40	6.43	4.98	4.36
Other Noncurrent Operating Assets	1.71	0.45	0.36	0.21	5.74	17	18	6.02	4.89
Total Liabilities & Shareholders' Equity	57	190	146	324	464	543	471	548	551
Total Liabilities	21	24	33	26	56	64	65	170	173
Total Current Liabilities	5.79	8.15	7.26	11	32	41	46	77	98
Accounts Payable	5.79	7.96	7.07	11	25	35	40	4.33	5.19
Accrued Expenses	-	-	-	-	-	-	-	50	65
Current Deferred Revenue	-	0.12	0.12	-	-	0.19	3.15	4.81	11
Other Current Liabilities	-	-	-	0.12	7.20	5.51	2.97	18	17
Total Noncurrent Liabilities	50	12	22	14	24	24	19	93	75
Noncurrent Deferred Revenue	0.68	0.44	0.32	-	-	-	-	-	1.70
Other Noncurrent Operating Liabilities	50	-	-	14	24	24	19	93	74
Commitments & Contingencies	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	0.97	166	113	299	408	479	405	378	377
Total Preferred & Common Equity	0.97	166	113	299	408	479	405	378	377
Total Common Equity	0.97	166	113	299	408	479	405	378	377
Common Stock	-	499	505	772	984	1,236	1,271	1,321	1,315
Retained Earnings	-	-352	-416	-472	-575	-756	-864	-942	-937
Accumulated Other Comprehensive Income / (Loss)	-	-0.88	-0.81	-0.81	-0.81	-0.85	-1.06	-0.73	-0.65

This table presents Aurinia Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025
Total Assets	482	488	452	549	555	517	524	549	505	503
Total Current Assets	453	460	424	416	426	398	410	440	406	409
Cash & Equivalents	152	86	89	82	46	64	33	37	66	53
Short-Term Investments	240	291	273	269	292	255	297	312	246	262
Accounts Receivable	18	42	19	19	38	29	26	36	40	40
Inventories, net	26	25	32	33	33	40	39	39	46	47
Prepaid Expenses	17	12	10	11	16	7.65	7.84	14	5.54	6.58
Other Current Assets	-	3.81	1.23	1.21	1.65	2.00	6.98	2.70	0.78	0.67
Plant, Property, & Equipment, net	4.18	3.76	3.84	3.65	3.50	3.20	3.04	2.89	2.58	2.42
Total Noncurrent Assets	25	25	24	129	125	115	111	106	97	91
Noncurrent Note & Lease Receivables	-	-	-	117	113	104	101	-	88	83
Intangible Assets	7.34	6.84	6.10	5.68	5.26	4.76	4.62	4.51	4.16	4.05
Other Noncurrent Operating Assets	17	18	18	6.23	6.13	5.90	5.16	102	4.78	3.93
Total Liabilities & Shareholders' Equity	482	488	452	549	555	517	524	549	505	503
Total Liabilities	58	65	61	157	163	157	159	161	155	167
Total Current Liabilities	35	42	42	62	74	71	77	79	68	78
Accounts Payable	32	40	36	41	52	50	56	57	4.22	3.31
Accrued Expenses	-	-	-	-	-	-	-	-	42	50
Current Deferred Revenue	-	-	3.16	3.23	4.66	4.91	4.37	4.30	4.59	5.50
Other Current Liabilities	2.25	1.64	2.92	17	17	16	16	18	17	20
Total Noncurrent Liabilities	24	23	19	95	89	86	82	83	86	89
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	-	12	12
Other Noncurrent Operating Liabilities	24	23	19	95	89	86	82	83	74	77
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	424	423	390	392	392	359	365	388	350	335
Total Preferred & Common Equity	424	423	390	392	392	359	365	388	350	335
Total Common Equity	424	423	390	392	392	359	365	388	350	335
Common Stock	1,255	1,263	1,282	1,295	1,308	1,313	1,318	1,326	1,264	1,228
Retained Earnings	-829	-838	-891	-902	-915	-953	-952	-938	-913	-892
Accumulated Other Comprehensive Income / (Loss)	-1.85	-1.53	-0.99	-1.02	-0.95	-0.85	-0.86	-0.39	-0.83	-0.91

This table displays calculated financial ratios and metrics derived from Aurinia Pharmaceuticals' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	141.62%	10.77%	-31.32%	15,660.38%	-9.00%	193.89%	30.95%	33.97%
EBITDA Growth	0.00%	-222.13%	23.93%	-66.47%	-14.64%	-72.29%	37.77%	16.45%	102.20%
EBIT Growth	0.00%	-203.89%	21.97%	-64.63%	-14.68%	-73.30%	38.32%	17.74%	94.89%
NOPAT Growth	0.00%	-87.27%	-17.86%	-64.63%	-14.68%	-73.30%	38.32%	17.74%	94.36%
Net Income Growth	0.00%	-203.89%	25.02%	-66.52%	-16.17%	-76.24%	40.22%	27.88%	107.37%
EPS Growth	0.00%	-39.39%	31.52%	-50.79%	8.42%	-60.92%	45.71%	28.95%	107.41%
Operating Cash Flow Growth	0.00%	-98.33%	-25.36%	-23.20%	-9.87%	-125.73%	49.57%	57.93%	232.66%
Free Cash Flow Firm Growth	0.00%	0.00%	45.44%	-1.04%	-49.64%	-135.99%	47.53%	6.98%	106.16%
Invested Capital Growth	0.00%	120.34%	58.84%	-159.38%	-101.63%	186.99%	23.30%	69.92%	-30.30%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-36.86%	3.90%	10.49%	6.70%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-16.09%	2.23%	1.51%	107.73%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-15.79%	3.97%	-1.75%	85.66%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-15.79%	3.97%	-1.75%	84.18%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-16.21%	6.30%	-1.07%	125.51%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-14.75%	7.32%	-1.89%	126.67%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-22.65%	31.38%	10.35%	55.28%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	30.28%	-8.20%	153.03%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	10.54%	-65.70%	-48.93%	-51.59%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	0.58%	100.00%	100.00%	100.00%	100.00%	97.61%	95.77%	91.94%	87.99%
EBITDA Margin	-12,720.23%	-16,958.85%	-11,647.30%	-28,230.19%	-205.35%	-388.80%	-82.32%	-52.52%	0.86%
Operating Margin	-14,466.47%	-11,212.44%	-11,930.89%	-28,598.43%	-208.09%	-396.31%	-83.17%	-52.24%	-1.99%
EBIT Margin	-13,465.32%	-16,935.89%	-11,930.89%	-28,598.43%	-208.09%	-396.31%	-83.17%	-52.24%	-1.99%
Profit (Net Income) Margin	-13,465.32%	-16,935.89%	-11,464.15%	-27,794.03%	-204.88%	-396.81%	-80.71%	-44.45%	2.45%
Tax Burden Percent	100.00%	100.00%	100.14%	100.16%	99.91%	100.42%	101.72%	100.71%	77.23%
Interest Burden Percent	100.00%	100.00%	95.96%	97.03%	98.55%	99.71%	95.41%	84.49%	-158.91%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	22.77%
Return on Invested Capital (ROIC)	0.00%	0.00%	-379.84%	-2,508.77%	0.00%	0.00%	-537.06%	-296.40%	-15.65%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-368.67%	-2,496.60%	0.00%	0.00%	-530.01%	-292.66%	-18.29%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	341.70%	2,465.78%	0.00%	0.00%	512.60%	276.48%	17.17%
Return on Equity (ROE)	-2,399.07%	-84.93%	-38.14%	-42.99%	-29.07%	-40.81%	-24.46%	-19.92%	1.52%
Cash Return on Invested Capital (CROIC)	0.00%	-1,008.79%	-425.30%	0.00%	0.00%	-1,187.17%	-557.93%	-348.21%	20.07%
Operating Return on Assets (OROA)	-40.87%	-57.36%	-32.91%	-38.69%	-26.47%	-35.89%	-21.98%	-18.00%	-0.85%
Return on Assets (ROA)	-40.87%	-57.36%	-31.62%	-37.60%	-26.06%	-35.94%	-21.33%	-15.31%	1.05%
Return on Common Equity (ROCE)	-2,399.07%	-84.93%	-38.14%	-42.99%	-29.07%	-40.81%	-24.46%	-19.92%	1.52%
Return on Equity Simple (ROE_SIMPLE)	-2,399.07%	-42.71%	-47.15%	-29.60%	-25.18%	-37.77%	-26.68%	-20.64%	1.52%
Net Operating Profit after Tax (NOPAT)	-18	-33	-39	-64	-73	-127	-78	-64	-3.62
NOPAT Margin	-10,126.53%	-7,848.71%	-8,351.62%	-20,018.90%	-145.66%	-277.41%	-58.22%	-36.57%	-1.54%
Net Nonoperating Expense Percent (NNEP)	-14.57%	-38.46%	-11.17%	-12.18%	-8.14%	-12.25%	-7.05%	-3.74%	2.64%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-19.25%	-16.98%	-0.96%
Cost of Revenue to Revenue	2.31%	0.00%	0.00%	0.00%	0.00%	2.39%	4.23%	8.06%	12.01%
SG&A Expenses to Revenue	4,028.90%	2,893.78%	2,957.67%	7,024.53%	194.09%	380.52%	146.51%	111.12%	73.16%
R&D to Revenue	8,401.16%	8,117.22%	8,937.80%	16,624.53%	100.42%	112.13%	33.57%	28.28%	8.84%
Operating Expenses to Revenue	14,564.16%	11,312.44%	12,318.57%	28,698.43%	308.09%	493.91%	178.94%	144.18%	89.98%
Earnings before Interest and Taxes (EBIT)	-23	-71	-55	-91	-104	-181	-111	-92	-4.69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-22	-71	-54	-90	-103	-177	-110	-92	2.03
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	5.09	5.80	3.79	6.19	1.51	3.42	3.41
Price to Tangible Book Value (P/TBV)	0.00	0.00	5.73	5.98	3.88	6.30	1.54	3.46	3.45
Price to Revenue (P/Rev)	0.00	0.00	1,238.08	5,447.28	30.85	65.03	4.58	7.36	5.47
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	223.53
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.45%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	37.55	0.00	0.00	192.08	13.99	34.49	48.80
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	1,013.23	4,484.95	22.42	54.81	1.68	5.36	3.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	457.46
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.89
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	199.75
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.07	0.19	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.07	0.19	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-40.83	-1.18	-0.93	-0.99	-1.03	-1.00	-0.97	-0.94	-0.94
Leverage Ratio	58.70	1.48	1.21	1.14	1.12	1.14	1.15	1.30	1.45
Compound Leverage Factor	58.70	1.48	1.16	1.11	1.10	1.13	1.09	1.10	-2.31
Debt to Total Capital	0.00%	6.64%	16.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	6.64%	16.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	93.36%	83.81%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.17	-0.40	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	2.28	1.93	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.17	-0.40	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.36	-0.56	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	4.93	2.69	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.36	-0.56	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.00	6.13	38.60	15.22	25.76	3.57	2.68	3.23
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	6.86	21.50	18.30	27.90	13.11	12.63	9.60	5.50	4.57
Quick Ratio	6.86	21.30	17.36	27.13	12.45	11.85	8.74	4.85	4.04
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-79	-43	-44	-65	-154	-81	-75	4.64
Operating Cash Flow to CapEx	0.00%	-164,676.00%	-69,744.59%	-74,805.88%	-951.36%	-10,505.80%	-27,235.96%	-4,660.31%	15,796.44%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-27.17	0.96
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-12.06	9.18
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-12.32	9.12
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.13	0.09	0.26	0.34	0.43
Accounts Receivable Turnover	2.01	4.29	2.84	1.09	0.00	0.00	9.28	9.34	7.76
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.07	0.26	0.44	0.72
Fixed Asset Turnover	0.00	0.00	12.86	4.75	20.54	9.91	33.23	50.12	77.28
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.04	0.15	0.64	5.94
Days Sales Outstanding (DSO)	181.45	85.14	128.50	335.73	0.00	0.00	39.35	39.07	47.06
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	5,562.49	1,420.24	831.45	509.96
Days Payable Outstanding (DPO)	528,428.75	0.00	0.00	0.00	0.00	9,993.84	2,414.55	571.66	61.47
Cash Conversion Cycle (CCC)	-528,247.30	85.14	128.50	335.73	0.00	-4,431.35	-954.96	298.86	495.55
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	-39	7.87	12	-7.42	-15	13	16	27	19
Invested Capital Turnover	0.00	-0.03	0.05	0.13	-4.48	-46.87	9.23	8.11	10.16
Increase / (Decrease) in Invested Capital	0.00	47	4.63	-20	-7.54	28	3.03	11	-8.26
Enterprise Value (EV)	0.00	0.00	469	1,426	1,123	2,499	225	940	927
Market Capitalization	0.00	0.00	573	1,732	1,546	2,966	614	1,291	1,286
Book Value per Share	$0.00	$1.97	$1.34	$3.49	$3.65	$3.69	$2.85	$2.63	$2.64
Tangible Book Value per Share	$0.00	$1.80	$1.19	$3.39	$3.56	$3.63	$2.81	$2.60	$2.61
Total Capital	0.97	178	134	299	408	479	405	378	377
Total Debt	0.00	12	22	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	12	22	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-40	-162	-104	-306	-423	-466	-389	-351	-358
Capital Expenditures (CapEx)	-0.02	0.03	0.07	0.09	7.34	1.50	0.29	0.72	0.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.71	-6.36	-0.27	-2.18	-11	6.60	7.04	-2.88	-9.64
Debt-free Net Working Capital (DFNWC)	34	167	126	304	387	473	396	348	349
Net Working Capital (NWC)	34	167	126	304	387	473	396	348	349
Net Nonoperating Expense (NNE)	5.78	38	14	25	30	54	30	14	-9.37
Net Nonoperating Obligations (NNO)	-40	-158	-100	-306	-423	-466	-389	-351	-358
Total Depreciation and Amortization (D&A)	1.29	-0.10	1.31	1.17	1.37	3.42	1.13	-0.49	6.71
Debt-free, Cash-free Net Working Capital to Revenue	-3,297.69%	-1,521.53%	-58.10%	-684.59%	-21.75%	14.47%	5.25%	-1.64%	-4.10%
Debt-free Net Working Capital to Revenue	19,620.81%	39,976.56%	27,124.62%	95,547.80%	773.04%	1,036.46%	295.78%	198.05%	148.36%
Net Working Capital to Revenue	19,620.81%	39,976.56%	27,124.62%	95,547.80%	773.04%	1,036.46%	295.78%	198.05%	148.36%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.92)	($0.76)	$0.00	($0.87)	($1.40)	($0.76)	($0.54)	$0.04
Adjusted Weighted Average Basic Shares Outstanding	0.00	84.05M	85.50M	111.80M	127.45M	141.65M	141.92M	143.24M	143.06M
Adjusted Diluted Earnings per Share	$0.00	($0.92)	($0.76)	$0.00	($0.87)	($1.40)	($0.76)	($0.54)	$0.04
Adjusted Weighted Average Diluted Shares Outstanding	0.00	84.05M	85.50M	111.80M	127.45M	141.65M	141.92M	143.24M	146.19M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.92)	($0.76)	$0.00	($0.87)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	84.05M	85.50M	111.80M	118.47M	129.37M	142.58M	144.62M	137.34M
Normalized Net Operating Profit after Tax (NOPAT)	-18	-33	-39	-64	-73	-127	-78	-64	14
Normalized NOPAT Margin	-10,126.53%	-7,848.71%	-8,351.62%	-20,018.90%	-145.66%	-277.41%	-58.22%	-36.57%	6.05%
Pre Tax Income Margin	-13,465.32%	-16,935.89%	-11,448.38%	-27,748.74%	-205.06%	-395.15%	-79.35%	-44.14%	3.17%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.04	-0.97
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-23.13	-0.75
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.30	-1.03
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-23.39	-0.81
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	699.57%

This table displays calculated financial ratios and metrics derived from Aurinia Pharmaceuticals' official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	21.50%	59.12%	47.19%	-2.27%	58.59%	46.19%	37.83%	24.32%	32.76%	24.18%	22.41%
EBITDA Growth	7.93%	14.70%	47.22%	-57.24%	4.79%	63.11%	101.11%	192.85%	100.76%	307.09%	10,819.02%
EBIT Growth	14.08%	21.90%	55.07%	-71.21%	-5.60%	55.20%	90.64%	172.24%	94.38%	264.85%	1,427.36%
NOPAT Growth	14.08%	21.90%	55.07%	-71.21%	-5.60%	55.20%	93.47%	200.01%	90.21%	325.77%	2,738.38%
Net Income Growth	21.84%	30.36%	67.64%	-49.59%	-3.18%	58.98%	106.28%	206.72%	105.32%	317.17%	2,879.64%
EPS Growth	25.00%	33.33%	68.00%	-50.00%	-5.56%	61.11%	112.50%	211.11%	0.00%	328.57%	1,500.00%
Operating Cash Flow Growth	140.31%	32.25%	89.86%	13.57%	36.96%	41.28%	660.62%	228.26%	110.41%	106.99%	179.25%
Free Cash Flow Firm Growth	55.37%	56.55%	57.16%	56.82%	-40.92%	2.20%	133.06%	241.84%	119.47%	216.46%	382.38%
Invested Capital Growth	23.30%	-1.69%	29.80%	14.12%	69.92%	36.33%	-18.37%	-26.47%	-30.30%	-5.27%	-40.58%
Revenue Q/Q Growth	-49.02%	21.01%	20.59%	31.38%	-17.28%	11.55%	13.70%	18.50%	-11.66%	4.34%	12.08%
EBITDA Q/Q Growth	-225.11%	-6.93%	41.42%	22.78%	-96.87%	58.57%	101.77%	6,348.78%	-98.38%	11,136.92%	-6.92%
EBIT Q/Q Growth	-195.82%	-5.28%	45.34%	-0.58%	-82.46%	55.34%	88.58%	876.47%	-114.21%	1,408.99%	-8.07%
NOPAT Q/Q Growth	-195.82%	-5.28%	45.34%	-0.58%	-82.46%	55.34%	92.03%	1,640.45%	-117.86%	1,130.14%	-6.90%
Net Income Q/Q Growth	-189.75%	-0.61%	56.15%	-17.01%	-99.86%	60.00%	106.72%	1,887.53%	-90.04%	1,533.59%	-7.84%
EPS Q/Q Growth	-200.00%	0.00%	55.56%	-12.50%	-111.11%	63.16%	114.29%	900.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	168.03%	-403.06%	91.08%	-369.82%	207.80%	-229.95%	185.19%	7.49%	76.84%	-95.68%	3,303.15%
Free Cash Flow Firm Q/Q Growth	45.50%	10.97%	-3.24%	13.79%	-77.83%	38.21%	134.89%	269.92%	-75.59%	269.60%	44.54%
Invested Capital Q/Q Growth	-65.70%	79.96%	44.00%	28.40%	-48.93%	44.38%	-13.78%	15.65%	-51.59%	96.24%	-45.91%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.21%	98.78%	96.23%	87.58%	88.04%	84.59%	84.42%	91.10%	90.73%	86.27%	89.84%
EBITDA Margin	-103.53%	-91.48%	-44.44%	-26.12%	-62.16%	-23.08%	0.36%	19.51%	0.36%	38.50%	31.97%
Operating Margin	-98.82%	-85.98%	-38.97%	-29.83%	-65.80%	-26.35%	-2.65%	17.33%	-2.79%	34.97%	28.69%
EBIT Margin	-98.82%	-85.98%	-38.97%	-29.83%	-65.80%	-26.35%	-2.65%	17.33%	-2.79%	34.97%	28.69%
Profit (Net Income) Margin	-91.60%	-76.16%	-27.70%	-24.67%	-59.60%	-21.37%	1.26%	21.17%	2.39%	37.37%	30.73%
Tax Burden Percent	103.39%	101.69%	94.71%	102.27%	101.74%	107.38%	48.85%	96.91%	121.82%	95.87%	97.10%
Interest Burden Percent	89.65%	87.11%	75.04%	80.85%	89.02%	75.53%	-97.69%	126.04%	-70.28%	111.45%	110.32%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	51.15%	3.09%	-21.82%	4.13%	2.90%
Return on Invested Capital (ROIC)	-638.14%	-303.40%	-118.67%	-66.23%	-373.34%	-103.46%	-7.09%	79.92%	-34.52%	216.35%	267.79%
ROIC Less NNEP Spread (ROIC-NNEP)	-636.65%	-302.00%	-118.63%	-65.66%	-371.69%	-103.03%	-7.52%	79.06%	-35.50%	215.59%	267.17%
Return on Net Nonoperating Assets (RNNOA)	615.74%	281.02%	107.92%	57.59%	351.14%	93.65%	6.77%	-69.67%	33.32%	-192.31%	-246.52%
Return on Equity (ROE)	-22.41%	-22.39%	-10.75%	-8.64%	-22.20%	-9.81%	-0.32%	10.25%	-1.20%	24.05%	21.28%
Cash Return on Invested Capital (CROIC)	-557.93%	-246.28%	-184.47%	-139.14%	-348.21%	-185.36%	-92.31%	-18.90%	20.07%	81.04%	237.46%
Operating Return on Assets (OROA)	-26.12%	-26.33%	-12.10%	-9.08%	-22.67%	-10.41%	-1.02%	6.92%	-1.19%	16.93%	14.54%
Return on Assets (ROA)	-24.21%	-23.33%	-8.60%	-7.51%	-20.53%	-8.45%	0.49%	8.45%	1.02%	18.09%	15.58%
Return on Common Equity (ROCE)	-22.41%	-22.39%	-10.75%	-8.64%	-22.20%	-9.81%	-0.32%	10.25%	-1.20%	24.05%	21.28%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-24.78%	-18.54%	-19.70%	0.00%	-17.40%	-13.81%	-5.81%	0.00%	11.38%	0.00%
Net Operating Profit after Tax (NOPAT)	-20	-21	-11	-11	-21	-9.28	-0.74	11	-2.03	21	20
NOPAT Margin	-69.18%	-60.18%	-27.28%	-20.88%	-46.06%	-18.44%	-1.29%	16.80%	-3.40%	33.53%	27.85%
Net Nonoperating Expense Percent (NNEP)	-1.49%	-1.41%	-0.05%	-0.58%	-1.65%	-0.43%	0.43%	0.86%	0.98%	0.76%	0.62%
Return On Investment Capital (ROIC_SIMPLE)	-4.85%	-	-	-	-5.50%	-	-	-	-0.54%	5.98%	5.82%
Cost of Revenue to Revenue	4.79%	1.22%	3.77%	12.42%	11.96%	15.41%	15.58%	8.91%	9.27%	13.73%	10.16%
SG&A Expenses to Revenue	166.95%	145.67%	113.46%	87.61%	111.04%	94.82%	78.57%	62.51%	61.86%	32.56%	37.16%
R&D to Revenue	34.71%	38.24%	30.49%	24.96%	22.68%	11.04%	7.13%	4.50%	13.54%	9.19%	10.62%
Operating Expenses to Revenue	194.03%	184.75%	135.20%	117.42%	153.84%	110.94%	87.07%	73.76%	93.51%	51.30%	61.15%
Earnings before Interest and Taxes (EBIT)	-28	-30	-16	-16	-30	-13	-1.51	12	-1.67	22	20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-29	-31	-18	-14	-28	-12	0.21	13	0.21	24	22
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.51	4.00	3.53	2.84	3.42	2.00	2.24	2.70	3.41	3.15	3.41
Price to Tangible Book Value (P/TBV)	1.54	4.07	3.58	2.88	3.46	2.03	2.27	2.73	3.45	3.19	3.45
Price to Revenue (P/Rev)	4.58	10.64	8.65	7.02	7.36	3.76	3.94	4.76	5.47	4.47	4.40
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	223.53	27.71	18.87
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.45%	3.61%	5.30%
Enterprise Value to Invested Capital (EV/IC)	13.99	41.60	24.86	14.53	34.49	10.15	14.32	17.82	48.80	21.22	41.11
Enterprise Value to Revenue (EV/Rev)	1.68	8.18	6.46	4.88	5.36	2.09	2.35	3.17	3.94	3.20	3.19
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	457.46	21.00	13.85
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	26.02	15.94
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	27.30	16.43
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	24.47	20.89	12.31	8.95
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	199.75	25.48	12.91
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.97	-0.93	-0.91	-0.88	-0.94	-0.91	-0.90	-0.88	-0.94	-0.89	-0.92
Leverage Ratio	1.15	1.14	1.26	1.28	1.30	1.29	1.42	1.42	1.45	1.44	1.47
Compound Leverage Factor	1.03	1.00	0.95	1.03	1.16	0.98	-1.38	1.78	-1.02	1.60	1.62
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	4.16	13.64	3.97	2.74	3.05	1.21	1.69	2.77	3.25	3.19	3.06
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.60	10.08	6.75	5.77	5.50	5.60	5.33	5.60	4.57	5.93	5.23
Quick Ratio	8.74	9.05	6.00	5.09	4.85	4.91	4.63	4.90	4.04	5.16	4.54
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-23	-20	-21	-18	-32	-20	6.90	26	6.23	23	33
Operating Cash Flow to CapEx	7,798.51%	-9,126.80%	-1,596.61%	0.00%	4,786.62%	0.00%	0.00%	0.00%	10,716.73%	7,647.06%	45,143.88%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-321.02	-12.85	-24.42	-15.41	5.76	21.12	5.44	21.58	29.79
Operating Cash Flow to Interest Expense	0.00	0.00	-43.48	-9.48	10.93	-14.50	13.22	14.10	26.28	1.22	39.61
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-46.20	-9.41	10.70	-14.50	13.22	14.10	26.03	1.20	39.52
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.26	0.31	0.31	0.30	0.34	0.40	0.39	0.40	0.43	0.48	0.51
Accounts Receivable Turnover	9.28	7.44	8.50	3.99	9.34	7.98	9.20	5.92	7.76	7.14	7.93
Inventory Turnover	0.26	0.20	0.20	0.35	0.44	0.60	0.80	0.79	0.72	0.68	0.64
Fixed Asset Turnover	33.23	35.92	40.88	43.80	50.12	54.38	61.89	69.05	77.28	85.66	95.21
Accounts Payable Turnover	0.15	0.17	0.16	0.22	0.64	0.50	0.59	0.52	5.94	1.07	0.91
Days Sales Outstanding (DSO)	39.35	49.04	42.94	91.58	39.07	45.72	39.67	61.64	47.06	51.11	46.04
Days Inventory Outstanding (DIO)	1,420.24	1,816.26	1,859.28	1,048.99	831.45	607.56	455.90	464.74	509.96	539.63	571.11
Days Payable Outstanding (DPO)	2,414.55	2,138.15	2,323.54	1,667.71	571.66	732.71	619.42	708.66	61.47	342.09	399.93
Cash Conversion Cycle (CCC)	-954.96	-272.85	-421.33	-527.13	298.86	-79.42	-123.85	-182.28	495.55	248.65	217.21
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	16	29	42	53	27	39	34	39	19	37	20
Invested Capital Turnover	9.23	5.04	4.35	3.17	8.11	5.61	5.48	4.76	10.16	6.45	9.61
Increase / (Decrease) in Invested Capital	3.03	-0.50	9.55	6.61	11	10	-7.64	-14	-8.26	-2.08	-14
Enterprise Value (EV)	225	1,201	1,034	776	940	399	486	699	927	791	829
Market Capitalization	614	1,563	1,385	1,114	1,291	719	817	1,048	1,286	1,104	1,144
Book Value per Share	$2.85	$2.74	$2.74	$2.73	$2.63	$2.50	$2.55	$2.71	$2.64	$2.55	$2.48
Tangible Book Value per Share	$2.81	$2.70	$2.70	$2.70	$2.60	$2.46	$2.52	$2.68	$2.61	$2.52	$2.45
Total Capital	405	390	392	392	378	359	365	388	377	350	335
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-389	-362	-351	-338	-351	-320	-331	-349	-358	-313	-315
Capital Expenditures (CapEx)	0.13	0.35	0.18	-0.11	0.30	0.00	0.00	0.00	0.28	0.02	0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	7.04	20	3.53	15	-2.88	7.26	2.29	13	-9.64	24	16
Debt-free Net Working Capital (DFNWC)	396	382	354	353	348	327	333	362	349	337	331
Net Working Capital (NWC)	396	382	354	353	348	327	333	362	349	337	331
Net Nonoperating Expense (NNE)	6.38	5.50	0.17	2.06	6.10	1.47	-1.46	-2.96	-3.46	-2.40	-2.01
Net Nonoperating Obligations (NNO)	-389	-362	-351	-338	-351	-320	-331	-349	-358	-313	-315
Total Depreciation and Amortization (D&A)	-1.34	-1.89	-2.27	2.03	1.64	1.64	1.72	1.47	1.88	2.20	2.30
Debt-free, Cash-free Net Working Capital to Revenue	5.25%	13.67%	2.21%	9.24%	-1.64%	3.79%	1.10%	5.95%	-4.10%	9.89%	5.99%
Debt-free Net Working Capital to Revenue	295.78%	259.92%	221.24%	221.95%	198.05%	170.93%	160.67%	164.21%	148.36%	136.42%	127.14%
Net Working Capital to Revenue	295.78%	259.92%	221.24%	221.95%	198.05%	170.93%	160.67%	164.21%	148.36%	136.42%	127.14%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.18)	($0.18)	($0.08)	($0.09)	($0.19)	($0.07)	$0.01	$0.10	$0.00	$0.17	$0.16
Adjusted Weighted Average Basic Shares Outstanding	141.92M	142.64M	142.78M	142.85M	143.24M	144.01M	143.33M	143.05M	143.06M	138.92M	134.87M
Adjusted Diluted Earnings per Share	($0.18)	($0.18)	($0.08)	($0.09)	($0.19)	($0.07)	$0.01	$0.10	$0.00	$0.16	$0.16
Adjusted Weighted Average Diluted Shares Outstanding	141.92M	142.64M	142.78M	142.85M	143.24M	144.01M	144.11M	145.65M	146.19M	143.20M	137.53M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	142.58M	143.03M	143.42M	143.61M	144.62M	143.02M	142.99M	143.18M	137.34M	135.10M	131.63M
Normalized Net Operating Profit after Tax (NOPAT)	-20	-21	-11	-11	-21	-4.60	-0.31	11	9.58	22	20
Normalized NOPAT Margin	-69.18%	-60.18%	-27.28%	-20.88%	-46.06%	-9.14%	-0.54%	16.80%	16.00%	35.88%	28.01%
Pre Tax Income Margin	-88.59%	-74.89%	-29.24%	-24.12%	-58.58%	-19.90%	2.58%	21.85%	1.96%	38.98%	31.65%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-248.77	-11.62	-22.65	-10.33	-1.26	9.73	-1.46	20.48	17.98
NOPAT to Interest Expense	0.00	0.00	-174.14	-8.13	-15.86	-7.23	-0.62	9.43	-1.77	19.63	17.46
EBIT Less CapEx to Interest Expense	0.00	0.00	-251.49	-11.54	-22.88	-10.33	-1.26	9.73	-1.70	20.46	17.89
NOPAT Less CapEx to Interest Expense	0.00	0.00	-176.86	-8.06	-16.08	-7.23	-0.62	9.43	-2.02	19.61	17.37
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	699.57%	187.88%	183.54%

Key Financial Trends

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported strong financial improvements in the second quarter of 2025 compared to the prior year and previous quarters, demonstrating growth in revenue, profitability, and operating cash flow.

Revenue Growth: Operating revenue increased from approximately $28.2 million in Q2 2022 to $70.0 million in Q2 2025, more than doubling over three years, indicating expanding sales.
Profitability Improvement: Aurinia went from substantial losses in 2022, where Q2 net loss was roughly -$35.5 million, to a consolidated net income of $21.5 million in Q2 2025, a significant turnaround.
Positive Operating Cash Flow: Net cash from operating activities was $44.2 million in Q2 2025, a marked improvement from negative operating cash flow in Q2 2022 (-$27.9 million), showing improved cash generation from core business.
Gross Profit Margin Expansion: Gross profit in Q2 2025 was approximately $62.9 million on $70.0 million revenue, reflecting improved cost control and pricing power.
Reduction in Operating Costs Relative to Revenue: Total operating expenses were $42.8 million in Q2 2025 vs. $49.8 million in Q3 2024 and higher in prior years, while revenue grew, signaling operational efficiency.

Stable Share Count: Weighted average diluted shares outstanding remained in the 130-140 million range, indicating moderate dilution, maintaining shareholder value stability.
Moderate Capital Expenditure: Capital expenditures remain low, about $100,000 in recent quarters, suggesting limited fixed asset investment, consistent with a pharma company focusing more on development than on heavy infrastructure.
Balanced Investment Activity: The company continues to purchase and sell investments frequently with net outflows, reflecting active management of its investment portfolio for liquidity and returns.
Tax Payments: Income tax expense remains relatively modest vis-à-vis income, around $0.6-1.0 million per quarter in profitable periods, consistent with their income levels.

Equity Repurchases Impact Cash: Substantial repurchases of common equity caused significant cash outflows (e.g., $42.6 million in Q2 2025), reducing net cash despite operating cash inflows.
Noncash Amortization Fluctuations: Negative amortization expense indicates non-cash accounting expenses that, while usual in pharma firms, add complexity to net income calculations.
Increasing Liabilities Over Time: Total liabilities have grown from approximately $58.3 million in Q2 2022 to $167.3 million in Q2 2025, mostly in current and noncurrent deferred revenue and accrued expenses, which may increase future obligations.
Negative Income in Early 2023 and 2024: The company reported net losses consistently through 2023 and early 2024, indicating past operational challenges before recent turnaround.
High Operating Expenses Historically: Operating expenses were high during loss periods, reaching over $55 million in some quarters of 2022 and 2023, which pressured profitability.

Summary: Aurinia Pharmaceuticals has demonstrated a clear positive trend with strong revenue growth, profitable quarters starting in 2024, and robust operating cash flow by Q2 2025. While the company paid down net cash partly through stock repurchases and carries rising liabilities, the improving profitability profile and cash generation are encouraging signs for investors. Monitoring future quarters will be important to see if the company maintains positive earnings and controls liabilities while sustaining growth.

08/28/25 11:52 PM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About Aurinia Pharmaceuticals' Financials

When does Aurinia Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Aurinia Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Aurinia Pharmaceuticals' net income changed over the last 8 years?

Aurinia Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $5.75 million in 2024, falling from -$23.30 million in 2016. The previous period was -$78.02 million in 2023. Check out Aurinia Pharmaceuticals' forecast to explore projected trends and price targets.

What is Aurinia Pharmaceuticals' operating income?

Aurinia Pharmaceuticals' total operating income in 2024 was -$4.69 million, based on the following breakdown:

Total Gross Profit: $206.89 million
Total Operating Expenses: $211.57 million

How has Aurinia Pharmaceuticals' revenue changed over the last 8 years?

Over the last 8 years, Aurinia Pharmaceuticals' total revenue changed from $173 thousand in 2016 to $235.13 million in 2024, a change of 135,815.0%.

How much debt does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals' total liabilities were at $173.17 million at the end of 2024, a 1.8% increase from 2023, and a 722.8% increase since 2016.

How much cash does Aurinia Pharmaceuticals have?

In the past 8 years, Aurinia Pharmaceuticals' cash and equivalents has ranged from $39.65 million in 2016 to $306.02 million in 2019, and is currently $83.43 million as of their latest financial filing in 2024.

How has Aurinia Pharmaceuticals' book value per share changed over the last 8 years?

Over the last 8 years, Aurinia Pharmaceuticals' book value per share changed from 0.00 in 2016 to 2.64 in 2024, a change of 263.6%.

Related Companies

This page (NASDAQ:AUPH) was last updated on 8/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Financials

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About Aurinia Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Financials

Annual Income Statements for Aurinia Pharmaceuticals

Quarterly Income Statements for Aurinia Pharmaceuticals

Annual Cash Flow Statements for Aurinia Pharmaceuticals

Quarterly Cash Flow Statements for Aurinia Pharmaceuticals

Annual Balance Sheets for Aurinia Pharmaceuticals

Quarterly Balance Sheets for Aurinia Pharmaceuticals

Annual Metrics And Ratios for Aurinia Pharmaceuticals

Quarterly Metrics And Ratios for Aurinia Pharmaceuticals

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About Aurinia Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools